BR0212052A - Preparação de composição farmacêutica de liberação prolongada - Google Patents

Preparação de composição farmacêutica de liberação prolongada

Info

Publication number
BR0212052A
BR0212052A BR0212052-6A BR0212052A BR0212052A BR 0212052 A BR0212052 A BR 0212052A BR 0212052 A BR0212052 A BR 0212052A BR 0212052 A BR0212052 A BR 0212052A
Authority
BR
Brazil
Prior art keywords
preparation
pharmaceutically active
pharmaceutical composition
release pharmaceutical
prolonged release
Prior art date
Application number
BR0212052-6A
Other languages
English (en)
Portuguese (pt)
Inventor
Serge R Martinod
Malcolm Brandon
Robert V Packard
Brian J Ward
Original Assignee
Smart Drug Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smart Drug Systems Inc filed Critical Smart Drug Systems Inc
Publication of BR0212052A publication Critical patent/BR0212052A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A61K9/2036—Silicones; Polysiloxanes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR0212052-6A 2001-09-11 2002-07-01 Preparação de composição farmacêutica de liberação prolongada BR0212052A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR761401 2001-09-11
PCT/AU2002/000868 WO2003022242A1 (en) 2001-09-11 2002-07-01 Preparation of sustained release pharmaceutical composition

Publications (1)

Publication Number Publication Date
BR0212052A true BR0212052A (pt) 2004-08-17

Family

ID=3831520

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212052-6A BR0212052A (pt) 2001-09-11 2002-07-01 Preparação de composição farmacêutica de liberação prolongada

Country Status (9)

Country Link
US (1) US20040234572A1 (https=)
EP (1) EP1424994A4 (https=)
JP (1) JP2005505557A (https=)
CN (1) CN1541090A (https=)
BR (1) BR0212052A (https=)
CA (1) CA2452194A1 (https=)
CO (1) CO5560533A2 (https=)
NZ (1) NZ530550A (https=)
WO (1) WO2003022242A1 (https=)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW586934B (en) * 1997-05-19 2004-05-11 Sumitomo Pharma Immunopotentiating composition
US20050129728A1 (en) * 2001-09-11 2005-06-16 Martinod Serge R. Sustained release pharmaceutical composition
US20050232972A1 (en) 2004-04-15 2005-10-20 Steven Odrich Drug delivery via punctal plug
CN101683317A (zh) * 2004-05-31 2010-03-31 斯玛特药物系统公司 缓释组合物
JP2008502605A (ja) 2004-06-16 2008-01-31 スマート ドラッグ システムズ インコーポレイティド 徐放性ワクチン組成物
DK1765454T3 (en) 2004-07-02 2016-05-02 Mati Therapeutics Inc Device for submission of treatment medium to eye
PT1781264E (pt) 2004-08-04 2013-10-16 Evonik Corp Métodos para o fabrico de dispositivis de administração e dispositivos para a mesma
US8864730B2 (en) 2005-04-12 2014-10-21 Rochester Medical Corporation Silicone rubber male external catheter with absorbent and adhesive
US9695953B2 (en) * 2006-02-14 2017-07-04 B. Braun Medical Inc. Needleless access port valves
US8015990B2 (en) * 2006-11-17 2011-09-13 B. Braun Medical Inc. Needleless access port valves
EP2004172B1 (en) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Drug delivery structures and compositions for nasolacrimal system
CA2698508C (en) 2007-09-07 2017-06-06 Alan R. Rapacki Lacrimal implants and related methods
NZ583858A (en) 2007-09-07 2012-08-31 Quadra Logic Tech Inc Lacrimal implant detection with detection device
AU2008300013A1 (en) * 2007-09-07 2009-03-19 Qlt Inc. Drug cores for sustained release of therapeutic agents
ES2718612T3 (es) 2007-12-20 2019-07-03 Evonik Corp Procedimiento para preparar micropartículas que tienen un bajo volumen de disolvente residual
WO2009134371A2 (en) 2008-04-30 2009-11-05 Qlt Plug Delivery, Inc. Composite lacrimal insert and related methods
CN102123713A (zh) 2008-05-09 2011-07-13 Qlt栓塞输送公司 治疗青光眼和眼高血压的活性剂的持续释放递送
KR20110132369A (ko) 2009-02-23 2011-12-07 큐엘티 인코포레이티드 눈물 임플란트 및 관련 방법
US9707375B2 (en) 2011-03-14 2017-07-18 Rochester Medical Corporation, a subsidiary of C. R. Bard, Inc. Catheter grip and method
US9974685B2 (en) 2011-08-29 2018-05-22 Mati Therapeutics Drug delivery system and methods of treating open angle glaucoma and ocular hypertension
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
US10092728B2 (en) 2012-11-20 2018-10-09 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Sheath for securing urinary catheter
US9872969B2 (en) 2012-11-20 2018-01-23 Rochester Medical Corporation, a subsidiary of C.R. Bard, Inc. Catheter in bag without additional packaging
EP2991621B1 (en) 2013-05-02 2020-12-09 Retina Foundation of the Southwest Two-layer ocular implant
CL2014000989A1 (es) * 2014-04-17 2014-10-17 Univ Santiago Chile Dispositivo subdermal de liberacion prolongada y lenta para prevencion, tratamiento y monitoreo de parasitos, que comprende al menos una lactona macrociclica tal como ivermectina y/o dormectina, opcionalmente nanoparticulas o microparticulas de zeolita, una matriz polimerica y medios de monitoreo, dentro de un circuito integrado.
AR101476A1 (es) 2014-08-07 2016-12-21 Acerta Pharma Bv Métodos para tratar cánceres, enfermedades inmunes y autoinmunes, y enfermedades inflamatorias en base a la tasa de ocupación de la tirosin quinasa de bruton (btk) y a la tasa de resíntesis de la tirosin quinasa de bruton (btk)
WO2016033234A1 (en) 2014-08-26 2016-03-03 C.R. Bard, Inc Urinary catheter
JP7350722B2 (ja) 2017-09-19 2023-09-26 シー・アール・バード・インコーポレーテッド 尿カテーテルブリッジ装置、そのシステムおよび方法
US20220168217A1 (en) * 2019-02-22 2022-06-02 Elkem Silicones USA Corp. Drug delivery silicone composition to improve active ingredient elution
US12589218B2 (en) 2020-08-03 2026-03-31 C. R. Bard, Inc. Intermittent-catheter assembly and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3279996A (en) * 1962-08-28 1966-10-18 Jr David M Long Polysiloxane carrier for controlled release of drugs and other agents
US4053580A (en) * 1975-01-01 1977-10-11 G. D. Searle & Co. Microsealed pharmaceutical delivery device
IE56979B1 (en) * 1984-02-14 1992-02-26 Drug Systems Res & Dev Subcutaneous implant
US5028430A (en) * 1987-05-08 1991-07-02 Syntex (U.S.A.) Inc. Delivery systems for the controlled administration of LHRH analogs
US4861596A (en) * 1988-03-21 1989-08-29 Pfizer Inc. Rolled matrix device having enhanced ability to unroll and method for its production
FR2653338B1 (fr) * 1989-10-23 1994-06-10 Dow Corning Sa Formulation pour des pansements a liberation prolongee de medicament et son utilisation.
JPH05238929A (ja) * 1992-02-27 1993-09-17 Sumitomo Pharmaceut Co Ltd 代謝性骨疾患治療用長期持続性製剤
PT810823E (pt) * 1995-02-24 2001-09-28 Novartis Ag Composicao para controlo de parasitas
US6395029B1 (en) * 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
US6998137B2 (en) * 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
AUPR602401A0 (en) * 2001-06-29 2001-07-26 Smart Drug Systems Inc Sustained release delivery system

Also Published As

Publication number Publication date
CO5560533A2 (es) 2005-09-30
CA2452194A1 (en) 2003-03-20
CN1541090A (zh) 2004-10-27
EP1424994A4 (en) 2004-12-01
EP1424994A1 (en) 2004-06-09
US20040234572A1 (en) 2004-11-25
NZ530550A (en) 2004-11-26
WO2003022242A1 (en) 2003-03-20
JP2005505557A (ja) 2005-02-24

Similar Documents

Publication Publication Date Title
BR0212052A (pt) Preparação de composição farmacêutica de liberação prolongada
BR0107869A (pt) Composições farmacêuticas eletrogiradas
BR9405798A (pt) Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
BR0002880A (pt) Composição farmacêutica de liberação controlada termoformável sólida
SV2002000245A (es) Oxazolidinonas substituidas y su uso ref. lea 34122-sv
BR122012030846B8 (pt) composição farmacêutica não aquosa para uso dermatológico compreendendo calcipotriol e pelo menos um corticoesteróide, e, uso da mesma
BR0309528A (pt) Comprimido com alta carga de droga
CY1105953T1 (el) Συνθεσεις για απελευθερωση συνδυασμων φαρμακων
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
BR0210631A (pt) Composição farmacêutica de liberação prolongada
BRPI0309868B1 (pt) métodos de preparação de uma composição de reduzida fração conjugada inferior
TR200502189T1 (tr) Kompozisyonlar ve farmakolojik etken maddelerin aktarımı için yöntemler.
UY27755A1 (es) Nuevas composiciones farmacéuticas basadas en anticolinérgicos e inhibidores.
BR9910583A (pt) Aminotetralinas n-substituìdas como ligantes para o receptor de neuropeptìdeo y y5 úteis no tratamento de obesidade e outros distúrbios
BRPI0213653B8 (pt) formulação farmacêutica que contém o 3-(3-dimetil-amino1-etil-2metil-propil) fenol e proporciona uma liberação retardada do ingrediente ativo
BR0212026A (pt) Sistema terapêutico transdérmico com fentanila ou substâncias análogas
BRPI0015567B8 (pt) composto, composição farmacêutica, forma de unidade de dosagem, uso da composição farmacêutica e método para preparar uma composição farmacêutica
CY1109880T1 (el) ΑΝΤΑΓΩΝΙΣΤΗΣ CaSR
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
BR9909329A (pt) Método para estabilizar composições farmacêuticas pelo uso especial de um antioxidante
BR0115965A (pt) Composições farmacêuticas para a liberação oral de agentes farmacologicamente ativos
BR9906920A (pt) "tts contendo um antioxidante"
BR0214159A (pt) Sistema farmacêutico radiopaco de liberação prolongada
BR0308137A (pt) Formulações de droga de liberação constante contendo um peptìdeo veìculo
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: VIRBAC CORPORATION (US)

Free format text: TRANSFERIDO DE: SMART DRUG SYSTEMS INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 13A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2313 DE 05-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.